This is the first treatment to be shown to reduce mortality in patients with Covid-19 requiring oxygen or ventilator support, says WHO chief
The World Health Organisation (WHO) has welcomed the initial clinical trial results from the United Kingdom that shows dexamethasone, a corticosteroid, can be lifesaving for patients who are critically ill with Covid-19.
The multilateral agency further said that it will “coordinate a meta-analysis to increase our overall understanding of this intervention.” The WHO clinical guidance will be updated to reflect how and when the drug should be used in Covid-19, it said. The agency already conducts the solidarity trial on probable Covid drugs and vaccines.
According to preliminary findings shared with the WHO, dexamethasone was seen to reduce mortality by about one third for patients on ventilators, and for patients requiring only oxygen, and the mortality was cut by about one fifth. The benefit was only seen in patients seriously ill with Covid-19, and was not observed in patients with milder disease.
“This is the first treatment to be shown to reduce mortality in patients with Covid-19 requiring oxygen or ventilator support,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General, congratulating the UK government, the University of Oxford, and the many hospitals and patients who were involved with the trial.
Dexamethasone is a steroid that has been used since the 1960s to reduce inflammation in a range of conditions, including inflammatory disorders and certain cancers. It has been listed on the WHO Model List of Essential Medicines since 1977 in multiple formulations, and is currently off-patent and isavailable at affordable prices in most countries. “Researchers shared initial insights about the results of the trial with WHO, and we are looking forward to the full data analysis in the coming days,” the WHO said.
The development builds off the WHO Research & Development Blueprint meeting, which took place in Geneva in mid-February to accelerate health technologies for Covid-19, where further research into the use of steroids was highlighted as a priority.
The findings reinforce the importance of large randomized control trials that produce actionable evidence. WHO will continue to work together with all partners to further develop lifesaving therapeutics and vaccines to tackle Covid-19, including under the umbrella of the Access to Covid-19 Tools Accelerator, the WHO said.
Thank you for being a loyal user of Portfolio.
Portfolio will be a paid section hereon.
Please Subscribe to get access to one of our early bird packs.
Or click on Free Trial to get 14 days free trial.
What You'll Get
-
Web + Mobile
Access exclusive content of the Hindu Businessline across desktops, tablet and mobile device.
-
Exclusive Portfolio and Investment Advice, Banking, Lifestyle and Specials
Get diverse set of perspectives from our trusted experts on Portfolio, Banking, Economy, Environment and others.
-
Ad free experience
Experience cleaner site with zero ads and faster load times.
-
Personalised dashboard
Customize your preference and get a personalized recommendation of stories based on your interest.
Published on
June 17, 2020
A letter from the Editor
Dear Readers,
The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.
Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.
In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.
We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.
But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.
I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.
A little help from you can make a huge difference to the cause of quality journalism!
Support Quality Journalism